KyungDong Pharm is joining forces with Protium Science to expand into biopharmaceutical development. On September 30, the companies signed a master services agreement (MSA) for biosimilar contract development at KyungDong Pharm’s Gwacheon headquarters. The ceremony was attended by KyungDong Pharm CEOs Ryu Ki-sung and Kim Kyung-hoon, Protium Science CEO Ahn Yong-ho and senior representatives of both companies. Protium Science specializes in biopharmaceutical contract development and analysis (CDAO). The agreement expands KyungDong Pharm’s R&D portfolio beyond small-molecule medicines into biopharmaceuticals. Collaboration will cover early-stage biosimilar cell line development, culture and purification process development, analysis and evaluation of biological drug substances, formulation development and quality characterization, and production of material for toxicology studies. CEO Ryu said, “As we mark our 50th anniversary and establish new sources of growth, it is particularly meaningful to work with Protium Science and its biopharmaceutical expertise. Through this agreement, we will develop globally competitive biosimilars and strengthen the foundation for KyungDong Pharm’s future growth.”